**Table 1 Demographics and clinical characteristics of the patients at baseline and follow-ups**

|  |  |
| --- | --- |
| **Demographic and clinical features** | **Number (percentage) Or Mean±SD** |
| Baseline（N=142） | 1 Month（N=137） | 3 Months（N=131） | 6 Months（N=128） | 12 Months（N=115） |
| Age, years (Mean ± SD) | 63.49±11.07 | 63.47±12.11 | 64.09±18.43 | 62.89±7.31 | 63.66±10.03 |
| GenderMaleFemale | 69 (48.59%)73 (51.41%) | 67 (48.91%)70 (51.09%) | 63 (48.09%)68 (51.91%) | 62 (48.44%)66 (51.56%) | 55 (48.59%)60 (51.41%) |
| EducationPrimary or lowerSecondaryTertiary or higher | 33 (23.24%)51 (35.92%)58 (40.85%) | 32 (23.36%)47 (34.31%)58 (42.34%) | 30 (22.90%)45 (34.35%)56 (42.75%) | 29 (22.66%)45 (35.16%)54 (42.19%) | 24 (20.87%)39 (33.91%)52 (45.22%) |
| Marital statusMarriedNot currently married | 98 (69.01%)44 (30.99%) | 96 (70.07%)41 (29.93%) | 97 (74.05%)34 (25.95%) | 95 (74.22%)33 (25.78%) | 93 (80.87%)22 (19.13%) |
| Area of residenceUrbanRural | 114 (80.28%)28 (19.72%) | 114(83.21%)23 (16.79%) | 109 (83.21%)22 (16.79%) | 106 (82.81%)22 (17.19%) | 94 (81.74%)21 (18.26%) |
| Income≥10,000RMB/month＜10,000RMB/month | 62 (43.66%)80 (56.34%) | 57(41.61%)80 (58.39%) | 56 (42.75%)75 (57.25%) | 55 (42.97%)73 (57.03%) | 45 (39.13%)70 (60.87%) |
| Eye affected by AMDRight/Left eye only | 112 (68.31%) | 109 (79.56%) | 107 (81.68%) | 106 (82.81%) | 93 (80.87%) |
| Both eyes | 30 (31.69%) | 28 (20.44%) | 24 (18.32%) | 22 (17.19%) | 22 (19.13%) |
| VA treated eye | 0.29±0.03 | 0.32±0.02 | 0.38±0.11 | 0.41±0.18 | 0.40±0.19 |
| BCVA | 0.51±0.12 | 0.48±0.03 | 0.58±0.07 | 0.62±0.21 | 0.58±0.16 |
| No. of intravitreal injections |  | 1.02±0.15 | 3.07±0.25 | 3.80±0.76 | 4.70±0.85 |

|  |  |
| --- | --- |
| **Demographic and clinical features** | **VFQ-25 score** |
| Baseline(N=142) | 1 month follow-up(N=137) | 3 months follow-up(N=131) | 6 months follow-up (N=128) | 12 months follow-up (N=115) |
| Gender  |  |  |  |  |  |
| Male  | 60.00±15.09（n=69） | 64.68±16.27\*（n=67） | 57.83±12.03\*\*（n=63） | 59.35±13.47\*\*（n=62） | 62.26±16.97（n=55） |
| Female | 58.23±17.54（n=73） | 58.93±15.89（n=70） | 51.12±14.38（n=68） | 53.51±11.16（n=66） | 56.71±19.25（n=60） |
| Education |  |  |  |  |  |
| Primary or lower | 55.41±18.99（n=33） | 58.18±19.51（n=32） | 42.83±9.01\*\*（n=30） | 54.23±13.46（n=29） | 58.54±19.22（n=24） |
| Secondary | 57.46±17.51（n=51） | 65.35±15.07（n=47） | 57.26±10.74（n=45） | 57.21±13.20（n=45） |  60.27±15.54（n=39） |
| Tertiary or higher | 62.62±12.97（n=58） | 60.79±14.93（n=58） | 58.17±13.67（n=56） | 56.74±11.76（n=54） | 59.37±18.33（n=52） |
| Marital status |  |  |  |  |  |
| Married | 63.12±17.23\*\*（n=98） | 63.37±16.44（n=96） | 54.47±13.67（n=97） | 57.19±12.90（n=95） | 58.34±18.29（n=93） |
| Not currently married | 50.11±9.4（n=44） | 57.93±15.41（n=41） | 53.98±13.88（n=34） |  53.90±11.64（n=33） | 63.71±18.28（n=22） |
| Area of residence |  |  |  |  |  |
| Urban | 61.02±16.64\*\*（n=114） | 61.80±14.08（n=114） | 55.15±14.58\*（n=109） | 57.21±12.90（n=106） | 60.04±18.37（n=94） |
| Rural | 51.26±12.69（n=28） | 61.47±24.87（n=23） | 50.36±6.67（n=22） | 52.16±10.51（n=22） | 56.33±18.25（n=21） |
| Income |  |  |  |  |  |
| ≥10,000RMB | 69.52±13.64\*\*（n=62） | 71.46±13.09\*\*（n=57） | 65.02±11.35\*\*（n=56） | 60.98±13.69\*\*（n=55） | 65.29±16.32\*\*（n=45） |
| <10,000RMB | 51.01±13.53（n=80） | 54.82±14.76（n=80） | 46.37±9.05（n=75） | 52.84±10.57（n=73） | 55.56±18.64（n=70） |
| Eye affected by AMD |  |  |  |  |  |
| Right/Left eye only | 61.23±16.05\*\*（n=112） | 63.97±15.52\*\*（n=109） | 55.63±14.30\*\*（n=107） | 56.83±13.14（n=106） | 61.16±17.46\*（n=93） |
| Both eyes | 51.12±15.26（n=30） | 53.10±16.55（n=28） | 48.62±8.54（n=24） | 53.97±9.71（n=22） | 51.78±20.33（n=22） |

**Table 2 Comparison of mean NEI VFQ-25 according to categorical variables at baseline and follow-ups**

**Table 3 Correlations between total score of the NEI VFQ-25 and continuous variables at baseline and follow-ups**

|  |  |
| --- | --- |
| **Variables** | **NEI VFQ-25 score** |
| Baseline | 1 month follow-up | 3 months follow-up | 6 months follow-up | 12 months follow-up |
| Age  | 0.151 | 0.147 | -0.050 | -0.070 | 0.062 |
| VA treated eye | 0.409\*\* | 0.231\*\* | 0.586\*\* | 0.063 | 0.193\* |
| BCVA | 0.608\*\* | 0.419\*\* | 0.550\*\* | 0.412\*\* | 0.443\*\* |
| No. of intravitreal injections |  | -0.045 | -0.125 | 0.115 | 0.136 |
| Anxiety | -0.130 | - 0.537\*\* | - 0.201\* | - 0.363\*\* | - 0.341\*\* |
| Depression | -0.270\*\* | - 0.533\*\* | - 0.237\*\* | - 0.798\*\* | - 0.656\*\* |
| Positive Coping | 0.053 | 0.068 | 0.140 | 0.363\*\* | 0.048 |
| Negative Coping | -0.259\*\* | - 0.075 | - 0.001 | - 0.328\*\* | -0.081 |
| Social Support | 0.007 | 0.165 | 0.285\*\* | 0.565\*\* | 0.427\*\* |
| Self-efficacy | 0.051 | 0.272\*\* | 0.300\*\* | 0.336\*\* | 0.616\*\* |

**Table 4. Linear regression analysis of baseline predictors of quality of life at baseline and follow-ups**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variables** | **Unstandardized Coefficients B** | **Std.Error** | **Standardized****Coefficients Beta** | **t** | **sig.** | **95% Confidence interval for B** |
| Lower Bound | Upper Bound |
| **Baseline** |
|  (Constant) | 79.843 | 6.135 | 　 | 13.015 | .000 | 67.712 | 91.975 |
|  BCVA | 24.499 | 3.494 | .458 | 7.012 | .000 | 17.589 | 31.408 |
|  Income | -8.652 | 2.204 | -.263 | -3.926 | .000 | -13.010 | -4.294 |
|  Depression | -7.454 | 2.304 | -.182 | -3.235 | .002 | -12.010 | -2.898 |
|  VA treated eye | 4.290 | 2.119 | .122 | 2.025 | .045 | 8.480 | 101.000 |
| **1 Month follow-up** |
|  (Constant) | 84.703 | 6.122 | 　 | 13.836 | .000 | 72.590 | 96.815 |
|  BCVA | 11.851 | 3.651 | .237 | 3.246 | .001 | 4.627 | 19.075 |
|  Income | -7.287 | 2.387 | -.228 | -3.052 | .003 | -12.011 | -2.563 |
|  Depression | -.529 | .235 | -.231 | -2.247 | .026 | -.994 | -.063 |
| **3 Months follow-up** |
|  (Constant) | 60.453 | 6.748 | 　 | 8.958 | .000 | 47.092 | 73.815 |
|  Anxiety | -.732 | .100 | -.495 | -7.288 | .000 | -.931 | -.533 |
|  VA treated eye | 34.764 | 5.160 | .551 | 6.738 | .000 | 24.549 | 44.980 |
|  Social Support | .278 | .053 | .272 | 5.216 | .000 | .384 | .173 |
|  Self-Efficacy | .684 | .136 | .316 | 5.034 | .000 | .415 | .953 |
|  Income | -6.337 | 1.399 | -.230 | -4.530 | .000 | -9.106 | -3.567 |
|  Education | 3.158 | .702 | .182 | 4.497 | .000 | 1.767 | 4.548 |
|  Depression | -.637 | .188 | -.279 | -3.383 | .001 | -.264 | -1.010 |
|  BCVA | 11.508 | 3.811 | .231 | 3.020 | .003 | 19.053 | 3.963 |
|  Area of residence | -4.835 | 1.906 | -.133 | -2.537 | .012 | -1.061 | -8.609 |
|  Gender | -2.786 | 1.151 | -.102 | -2.422 | .017 | -5.064 | -.508 |
| **6 Months follow-up** |
|  (Constant) | 105.511 | 11.282 | 　 | 9.352 | .000 | 83.169 | 127.854 |
|  Depression | -1.974 | .179 | -1.690 | -11.025 | .000 | -2.329 | -1.620 |
|  Anxiety | 1.902 | .275 | .945 | 6.910 | .000 | 1.357 | 2.447 |
|  Negative coping | -1.397 | .270 | -.325 | -5.175 | .000 | -1.931 | -.862 |
|  Social Support | .430 | .096 | .275 | 4.467 | .000 | .240 | .621 |
|  Positive coping | .823 | .189 | .243 | 4.350 | .000 | .448 | 1.198 |
|  Gender | -6.563 | 1.553 | -.261 | -4.227 | .000 | -9.638 | -3.488 |
|  Self-Efficacy | -.606 | .141 | -.264 | 4.307 | .000 | -.885 | -.328 |
|  BCVA | 14.622 | 3.728 | .247 | 3.922 | .000 | 22.004 | 7.240 |
|  Income | -3.466 | 1.439 | -.136 | -2.408 | .018 | -6.316 | -.615 |
| **12 Months follow-up** |
|  (Constant) | 26.270 | 10.321 | 　 | 2.545 | .012 | 5.814 | 46.726 |
|  Self–Efficacy | 1.082 | .187 | .424 | 5.785 | .000 | .711 | 1.452 |
|  BCVA | 19.478 | 4.658 | .285 | 4.181 | .000 | 10.245 | 28.710 |
|  Depression | -.316 | .114 | -.196 | -2.759 | .007 | -.542 | -.089 |
|  Eye affected by AMD | -8.737 | 3.216 | -.188 | -2.717 | .008 | -15.112 | -2.363 |
|  Social Support | .215 | .093 | .173 | 2.302 | .023 | .030 | .400 |